CMS Finalizes Flat-Rate Rule for Skin Substitutes

Note: This article is written for web publication in standard American English and is based on current U.S. policy and industry reporting as of 2026. It is for informational purposes only and does not replace legal, billing, reimbursement, or clinical advice.

Medicare policy updates are usually the kind of thing that make normal people reach for coffee, then a second coffee, then maybe a nap. But the Centers for Medicare & Medicaid Services just finalized a skin substitute payment change that is too big for the wound care world to ignore. For 2026, CMS has moved many skin substitutes away from the old product-by-product reimbursement model and into a standardized flat-rate framework. In plain English: the government looked at a market full of sky-high prices, weird incentives, and growing scrutiny, and said, “We are not doing this the old way anymore.”

That matters because skin substitutes are not niche curiosities anymore. They are widely used in the treatment of chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Medicare spending on these products has exploded. CMS concluded that the prior payment approach encouraged inflated launch prices and aggressive billing behavior, especially in physician office settings. The agency’s answer was to create a simpler, more controlled reimbursement structure for many products used in covered application procedures.

The final rule does not erase every debate. Providers worry about access. Manufacturers worry about innovation. Hospitals and physician practices worry about workflow, margins, coding, and compliance. And because this is health care policy, nothing arrives without a side dish of confusion. Still, the direction of travel is now clear: CMS wants payment for skin substitutes to be more predictable, more evidence-sensitive, and less vulnerable to runaway spending.

What CMS Actually Finalized

At the center of the rule is a major payment redesign. CMS finalized a policy under which many skin substitute products used in covered application procedures will no longer be reimbursed through the old average sales price style methodology that gave each product its own payment limit. Instead, for calendar year 2026, most skin substitutes that are not licensed as biologicals under Section 351 of the Public Health Service Act are treated as incident-to supplies and paid using a standardized amount.

That standardized amount is essentially a flat rate for 2026. CMS finalized a single national payment rate of about $127.28 per square centimeter under the Physician Fee Schedule, while outpatient hospital analyses describe a closely related OPPS rate of about $127.14 per unit. The tiny difference does not change the broader story: the agency intentionally moved away from wildly variable product-specific payment and toward a much more uniform structure.

CMS also aligned product categorization with FDA regulatory pathways. Instead of sorting products mainly by sticker price or legacy billing conventions, the agency grouped them by regulatory status. The major categories include:

• Premarket Approval (PMA) products
• 510(k)-cleared products, including De Novo devices
• 361 human cells, tissues, and cellular and tissue-based products (HCT/Ps)

For 2026, however, CMS chose to use one payment amount across those categories, based on the highest average among them. In other words, the agency created categories, then temporarily used one rate across the categories so it would not underestimate resource needs in year one. CMS has already signaled that future rulemaking may introduce differentiated payment rates by category once the new structure has a year of real-world experience under its belt.

What Stayed Outside the Flat-Rate System

Not every product is swept into this new framework. Skin substitutes that are licensed as biologicals under Section 351 of the Public Health Service Act continue to be paid under the ASP-based methodology. That distinction is important because it means the rule is not a total wipeout of existing reimbursement logic. It is more like a major redrawing of the map, with a few old roads still open.

Why CMS Made This Move

CMS did not wake up one morning and decide flat rates were trendy. The agency acted because spending on skin substitutes shot up at a pace that set off policy alarm bells, budget alarm bells, and probably a few office coffee machines in Washington.

According to CMS, Part B spending for these products rose from about $252 million in 2019 to more than $10 billion in 2024. MedPAC’s public data book paints the same picture and notes that between 2021 and 2024, spending jumped about 890 percent. The Office of Inspector General also warned that spending had skyrocketed, driven by both utilization and higher prices, and said the category appeared particularly vulnerable to questionable billing and fraud schemes.

That combination is policy dynamite. Once a product category starts looking like a magnet for inflated pricing, spread-based profits, and billing patterns that do not square with patient need, reform becomes much more likely. CMS explicitly tied the final payment change to its effort to improve payment accuracy and reduce spending waste. The agency projected that the new rule would reduce gross fee-for-service program spending on skin substitute services by about $19.6 billion in 2026.

That is not a trim. That is a haircut so aggressive the mirror needs a minute.

How the Old System Worked, and Why CMS Thought It Broke

Before the 2026 change, payment looked different depending on where care was delivered. In the physician office, many skin substitutes were paid more like biologicals, using a product-specific ASP-based methodology. In the hospital outpatient setting, products were generally packaged into the related application procedure and split into high-cost and low-cost groups.

That mismatch created two very different incentive environments. MedPAC observed that most of the spending explosion occurred in the non-facility setting, not in the OPPS. Under product-specific reimbursement, manufacturers could launch at eye-popping prices, and providers had reason to favor products that created a bigger spread between acquisition cost and reimbursement. CMS repeatedly signaled that this was not a healthy setup for the Medicare program, beneficiaries, or long-term payment integrity.

The flat-rate rule is CMS’s attempt to sever the link between a product’s launch price and the reimbursement jackpot it might produce. Once payment is standardized, the business strategy of “price it high and bill enthusiastically” becomes much less attractive.

What the Final Rule Means for Wound Care Providers

For physicians, hospital outpatient departments, and wound care centers, this rule is not just a spreadsheet event. It changes the economics of product selection, inventory planning, documentation, and claims strategy.

1. Product selection will become more evidence-driven

Under a flat-rate structure, providers have less reason to chase a product simply because its reimbursement used to be richer. That pushes practices to ask harder questions: Which products have the strongest clinical evidence? Which are easiest to source? Which work best for specific wound types? Which can be used without blowing up margins?

2. Documentation matters even more

When payment tightens, scrutiny usually rises. Practices should expect more attention to wound measurements, standard-of-care history, debridement records, offloading or compression use, product waste, frequency of applications, and medical necessity. The reimbursement rule may be new, but compliance headaches are timeless.

3. Budgeting gets easier, but revenue forecasting gets harsher

A standardized payment rate is easier to model than dozens of product-specific payment limits. The catch is that some providers who previously benefited from higher-paid products may see a significant revenue reset. A simpler formula does not automatically mean a happier finance team.

4. Inventory strategy becomes a survival skill

Practices that once kept a broad shelf of premium products may narrow their formularies. Purchasing teams will likely negotiate harder, compare costs more aggressively, and favor products with a stronger balance of evidence, availability, and economics.

What the Rule Means for Hospitals and OPPS Payment

CMS also finalized related changes in the hospital outpatient setting. Historically, skin substitutes in OPPS were packaged into the associated application procedures, with products divided into high-cost and low-cost groups. For 2026, CMS unbundled many skin substitute products from the application service and established new APC structures based on product characteristics tied to FDA regulatory status.

This is one of the more debated parts of the policy. MedPAC supported reform in the physician office setting but opposed unbundling under OPPS, arguing that packaging is a core feature of the outpatient payment system and that the spending problem was primarily concentrated in the non-facility setting. CMS nevertheless finalized the cross-setting alignment approach, favoring consistency between hospital outpatient departments and physician offices.

That decision tells providers something important about agency thinking: CMS cares not only about reducing spending, but also about making payment logic line up across settings. The agency appears to believe that if one site of care gets a radically different reimbursement treatment, incentives can shift in ways that distort where and how services are delivered.

Industry Reaction: Support, Skepticism, and a Lot of Nervous Calculators

The reaction has been mixed, which in reimbursement policy is basically the official sound of “this is a big deal.”

CMS and supportive analysts argue the rule restores sanity to a market that had become detached from clinical and economic reality. MedPAC broadly backed the agency’s effort to reform payment in the non-facility setting and praised the move toward grouping clinically similar products. The OIG’s warning about fraud, waste, and abuse also gave reformers a powerful policy tailwind.

On the other side, provider groups such as the American Podiatric Medical Association said reform was needed but argued the proposal risked unintended consequences for patients with chronic wounds and the clinicians treating them. That concern is not trivial. If reimbursement falls too hard or too fast, some practices may reduce access to certain products, especially in cases where acquisition costs remain high and clinical alternatives are limited.

In short, one camp sees the flat-rate rule as long-overdue market discipline. The other sees a blunt instrument that could solve abuse while creating new access problems. Both views have real logic behind them.

The Coverage Plot Twist: Payment Changed, But LCDs Took a Different Path

Just to keep things lively, the reimbursement overhaul landed against a messy coverage backdrop. In April 2025, CMS delayed the effective date of certain final Local Coverage Determinations for skin substitute grafts while the agency reviewed evidence and policy. Then, in December 2025, CMS announced that the MACs were withdrawing those LCDs altogether before the scheduled January 1, 2026 effective date.

That means providers entered 2026 with a major payment reform in place, but without the expected LCD tightening that many had been planning around. Operationally, that is awkward. It leaves organizations trying to manage a stricter economic framework while still watching for future coverage developments. If you work in revenue cycle, you probably call that “character building.”

Specific Examples of How This Could Play Out

Example one: a wound clinic that previously relied on several premium-priced products may now discover that reimbursement no longer justifies carrying the entire set. The clinic could respond by narrowing its preferred product list, requiring stronger internal approval for certain applications, and negotiating harder with vendors.

Example two: a hospital outpatient department may need to retrain coding and billing staff because skin substitutes are no longer treated under the old packaged assumptions. Finance, supply chain, and clinical leadership now have to speak the same language, which is wonderful in theory and occasionally comedic in practice.

Example three: a physician practice with strong documentation, consistent wound protocols, and disciplined product use may adapt more smoothly than a practice that historically leaned on expensive products with thin workflow controls. The new rule rewards operational maturity almost as much as clinical judgment.

What to Watch Next

The 2026 policy looks final, but it does not look permanent in its current shape. CMS has already indicated that future payment rates may vary by FDA category rather than sharing one temporary single rate. That means 2026 is likely the first chapter, not the last one.

Stakeholders should watch for several things:

• Whether CMS proposes distinct future rates for PMA, 510(k), and 361 HCT/P products
• Whether additional coverage criteria or MAC-level policies return in a revised form
• Whether acquisition costs and vendor pricing adjust downward in response to standardized reimbursement
• Whether access concerns emerge in rural, high-risk, or specialty wound care populations
• Whether compliance enforcement around wound care and skin substitute billing intensifies further

Bottom Line

CMS’s finalized flat-rate rule for skin substitutes is one of the most important recent payment changes in wound care. It is designed to stop a spending surge, weaken incentives for inflated pricing, and bring more structure to a Medicare category that had become increasingly hard to defend. For some providers, it will feel like overdue reform. For others, it will feel like a financial shock with paperwork attached.

Either way, the old reimbursement era is over. The winners in this new environment will likely be organizations that combine strong evidence standards, disciplined documentation, smart purchasing, and careful coding. The losing strategy is pretending nothing changed. CMS changed the math. Everyone else now has to change the playbook.

Field Experience and Practical Lessons From the 2026 Shift

One of the most interesting things about the CMS final rule is how quickly it moved from policy paper to daily operational reality. In conversations across the wound care space, the most common reaction has not been dramatic outrage or celebration. It has been something more practical: “Okay, what do we do on Monday morning?” That question says a lot. The rule is big, but the real story is how it changes ordinary work inside clinics, outpatient departments, and physician offices.

A common pattern is that administrators and clinicians are suddenly sitting in the same room more often. Before the rule, some product decisions could quietly ride along on old reimbursement assumptions. Now they cannot. Clinical leaders want to preserve flexibility for difficult wounds. Revenue cycle teams want fewer surprises. Purchasing teams want to know which products will still make sense under a standardized rate. Compliance teams want documentation that can survive scrutiny. Nobody gets to stay in a silo anymore.

Another real-world experience is that product conversations have become sharper and, frankly, healthier. Teams are asking whether a product has meaningful evidence, whether it performs well for a defined wound population, and whether there is a lower-cost option that achieves a similar result. That does not mean the cheapest product always wins. It means the “because we have always used it” argument is getting weaker by the day.

There is also a workflow lesson here. Practices that already had strong protocols for wound measurement, standard-of-care prerequisites, and follow-up intervals tend to feel more prepared. They may not love the payment cut, but they know how to operate in a tighter reimbursement environment. By contrast, organizations that depended on loose product selection rules or inconsistent documentation are learning that a flat-rate system can expose operational weaknesses very quickly.

Staff education is another major theme. Billing teams need updated guidance. Clinicians need clarity on which products fall into which regulatory buckets. Schedulers, coders, and supply staff need to understand that this is not just a line-item revision buried in a federal document. It changes margins, inventory decisions, and claim risk. The most successful organizations are treating the rule as a cross-functional project, not a billing footnote.

Finally, there is the patient-facing side. Most patients never ask whether a graft sits in a PMA or 361 HCT/P category, and honestly, good for them. What they care about is whether care is available, timely, and appropriate. That is why the biggest practical challenge for providers is balancing economics with access. The organizations that handle this well are the ones building a clear internal framework: use strong standard-of-care first, document response carefully, choose products with purpose, and be prepared to explain why each application was reasonable and necessary. That is not flashy. But in 2026, it is probably the closest thing wound care has to a superpower.

SEO Tags